Related Experiment Video

Updated: Aug 7, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

Sunanda Singh1, Hector J Gomez1, Shreya Thakkar2

  • 1Singh Biotechnology, 1547 Fox Grape Loop, Lutz, FL 33558, USA.

International Journal of Molecular Sciences
|March 11, 2023
PubMed

Insights

Acquired drug resistance (ADR) limits cancer therapy effectiveness. This review highlights how the STAT3 pathway mediates resistance to 24+ anti-cancer drugs, suggesting STAT3 targeting as a strategy to overcome ADR.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Combination cancer therapies can achieve durable remission but often face acquired drug resistance (ADR).
  • The Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway is implicated in various cellular processes, including cancer progression and drug resistance.
  • Understanding the mechanisms of ADR is crucial for developing more effective and durable cancer treatments.

Purpose of the Study:

  • To review the scientific literature on STAT3-mediated mechanisms of acquired drug resistance to anti-neoplastic agents.
  • To identify the range of anti-cancer therapies affected by STAT3-driven resistance.
  • To evaluate the potential of targeting STAT3 to overcome or prevent drug resistance in cancer treatment.

Main Methods:

  • Comprehensive literature review of scientific and medical publications.
  • Analysis of studies investigating the role of the STAT3 signaling pathway in acquired drug resistance.
  • Categorization of anti-neoplastic agents that utilize STAT3 for resistance development.

Main Results:

  • At least 24 different anti-neoplastic agents, including chemotherapeutics, kinase inhibitors, anti-hormonal agents, and monoclonal antibodies, were found to utilize the STAT3 pathway in developing acquired drug resistance.
  • The STAT3 signaling pathway is a common mechanism underlying resistance to a broad spectrum of cancer therapeutics.
  • Evidence suggests STAT3 plays a significant role in mediating resistance across diverse cancer types and treatment modalities.

Conclusions:

  • The STAT3 signaling pathway is a key mediator of acquired drug resistance to a wide array of anti-cancer therapies.
  • Targeting STAT3, in conjunction with current anti-neoplastic agents, presents a promising strategy to prevent or overcome acquired drug resistance.
  • Further research into STAT3 inhibition could lead to improved therapeutic outcomes and durable remission in cancer patients.
Keywords:
STAT3acquired drug resistancechemotherapyimmune checkpoint inhibitionkinase inhibitorsmonoclonal antibodies

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K